ANEBULO PHARMACEUTICALS, INC.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, has completed dosing in a Phase 2 clinical trial evaluating its utility in reversing the negative effects of acute cannabinoid intoxication. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1).
Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.